To maintain the protective properties of adiponectin in obesity and prevent the development of T2D, obesity, and cardiovascular disease, the current therapeutic approach with the use of pharmacological interventions focuses on restoring increased AT-associated adipokine secretion. This evidence concerns the gene ADIPOQ and type 2 diabetes mellitus.